glioblastoma

Kintara Therapeutics Inc (NASDAQ: KTRA) announced topline data results from the newly diagnosed adjuvant arm of its Phase 2 clinical study. The Phase 2 trial is testing VAL-083 in glioblastoma multiforme (GBM) patients who have an unmethylated promoter of the methylguanine DNA-...

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for glioblastoma multiforme (GBM) and other malignant gliomas. The news follows the recent announcement of the FDA granting LP-184 Orphan Drug tag for pancreatic cancer. LP-184 is a small molecule drug...

Document Security Systems Inc's (NYSE: DSS) subsidiary, DSS Biomedical International, Inc., has completed a $1 million equity investment in Vivacitas Oncology, Inc. Vivacitas Oncology focuses on developing new treatment options to treat cancers resistant to currently...

The Data and Safety Monitoring Board has recommended Plus Therapeutics Inc (NASDAQ: PSTV) to proceed to the eighth cohort of Phase 1 dose-escalation ReSPECT trial evaluating Rhenium NanoLiposome (RNL) for recurrent glioblastoma. The eighth cohort of the ReSPECT trial will implement...

Kintara Therapeutics Inc (NASDAQ: KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase 2/3 trial for glioblastoma multiforme (GBM) has been activated. The trial, titled GBM AGILE, is a patient-centered, adaptive platform...

Yumanity Therapeutics (NASDAQ: YMTX) has announced results from preclinical studies of YTX-7739 in glioblastoma multiforme (GBM). Researchers at the Massachusetts General Hospital conducted the study. Data demonstrated in vivo efficacy, including increased median overall...

Glioblastoma is a rare type of brain cancer thrust into the spotlight after it was reported Sen. John McCain has been diagnosed with the very aggressive disease. Glioblastoma affects 15,000–17,000 new patients in the United States every year, and treatment options haven’t changed much...

Glioblastoma is a rare form of brain cancer that sees less than 200,000 new cases in the United States annually. Vancouver-based Biotech company DelMar Pharmaceuticals Inc (NASDAQ: DMPI) is making significant strides in fighting this rare disease. With maximum treatment, glioblastoma remains a...